Annotation Detail

Information
Associated Genes
ROS1
Associated Variants
ROS1 CD74-ROS1 G2032R
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1101
Gene URL
https://civic.genome.wustl.edu/links/genes/4941
Variant URL
https://civic.genome.wustl.edu/links/variants/465
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Cabozantinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
25351743
Drugs
Drug NameSensitivitySupported
CabozantinibSensitivitytrue